Trial Profile
A Double-blind, Placebo- and Active-controlled Evaluation of the Safety and Efficacy of Levomilnacipran ER in Pediatric Patients 7-17 Years With Major Depressive Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2022
Price :
$35
*
At a glance
- Drugs Levomilnacipran (Primary) ; Fluoxetine
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors AbbVie; Allergan
- 02 Mar 2021 Status changed from active, no longer recruiting to completed.
- 16 Dec 2020 Planned End Date changed from 19 May 2021 to 26 Mar 2021.
- 16 Dec 2020 Planned primary completion date changed from 19 May 2021 to 26 Mar 2021.